Around 2000 pPTCs with associated molecular data have been published to date, and RET gene fusions to various gene partners (most commonly CCDC6 and NCOA4, termed PTC1 and PTC3 respectively) seem to be the most common fusion event in this tumor category, detected in approximately 25–30% of all cases – thereby alone occurring at similar frequencies as the BRAF V600E mutation (Paulson et al. 2019). The gene discussed is NCOA4; the disease is neoplasm.